Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.

European Multidisciplinary Conference in Thoracic Oncology (EMCTO) 2013

FDA approves erlotinib with EGFR mutation test for advanced NSCLC

FDA approves erlotinib with EGFR mutation test for advanced NSCLC

EMCTO 2013: Initial results from the largest prospective study of pulmonary metastasectomy in patients with colorectal cancer

EMCTO 2013: Initial results from the largest prospective study of pulmonary metastasectomy in patients with...

EMCTO 2013: Stereotactic ablative radiotherapy is an effective alternative in patients with multiple primary lung cancers

EMCTO 2013: Stereotactic ablative radiotherapy is an effective alternative in patients with multiple primary lung...

EMCTO 2013: Evaluation of performance of lung cancer screening strategy in the first three rounds of the NELSON trial

EMCTO 2013: Evaluation of performance of lung cancer screening strategy in the first three rounds of the NELSON...

EMCTO 2013: Different survival outcome following diagnosis of metastatic bone disease shown for EGFR mutated NSCLC patients in small retrospective study

EMCTO 2013: Different survival outcome following diagnosis of metastatic bone disease shown for EGFR mutated NSCLC...

EMCTO 2013: Meta-analysis slightly favours platinum-based first-line treatment in patients with advanced/metastatic NSCLC

EMCTO 2013: Meta-analysis slightly favours platinum-based first-line treatment in patients with advanced...

EMCTO 2013: A study of simultaneous occurrence of EGFR mutations and HER2 gene amplifications in large series of NSCLC

EMCTO 2013: A study of simultaneous occurrence of EGFR mutations and HER2 gene amplifications in large series of...

EMCTO 2013: First-line gefitinib effective and well tolerated in Caucasian patients with EGFR mutation-positive NSCLC

EMCTO 2013: First-line gefitinib effective and well tolerated in Caucasian patients with EGFR mutation-positive...

EMCTO 2013: Enobosarm improves muscle wasting experienced by patients with NSCLC

EMCTO 2013: Enobosarm improves muscle wasting experienced by patients with NSCLC

EMCTO 2013: Findings support the value of tumour rebiopsy in NSCLC patients

EMCTO 2013: Findings support the value of tumour rebiopsy in NSCLC patients

More from ecancer